Literature DB >> 6785416

Sodium valproate enhancement of gamma-aminobutyric acid (GABA) inhibition: electrophysiological evidence for anticonvulsant activity.

F Baldino, H M Geller.   

Abstract

The purpose of this study was to gain further insight into the mechanism of action of the anticonvulsant sodium valproate. The effects of valproate on spontaneous neuronal activity and its interaction with locally applied gamma-aminobutyric acid (GABA) were assessed in the rat cerebral cortex. Extracellular neuronal potentials were recorded using standard procedures. Valproate, glycine, GABA and bicuculline methiodide were applied through microiontophoresis. Valproate at 30, 50, and 100 nA did not affect the spontaneous activity of the majority of cells (21), increased the firing rate in four and slowed right cells. When applied simultaneously with GABA, valproate significantly enhanced GABA inhibition in a dose-related manner. Bicuculline methiodide antagonized the combined effects of valproate and GABA. Glycine inhibitions were not significantly enhanced by valproate. Our results indicate that valproate enhances GABA inhibition in the cerebral cortex, an action which is independent of its effect on spontaneous activity. The specificity of valproate for GABA suggests that this interaction may be an important mechanism through which valproate exerts its anticonvulsant properties.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6785416

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture.

Authors:  C Zona; M Avoli
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

Review 2.  Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management.

Authors:  Mohamed Naguib; Robert Koorn
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Mechanisms of anticonvulsant drug action. II. Drugs primarily used for absence epilepsy.

Authors:  C L Faingold; R A Browning
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

4.  Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex.

Authors:  Gabriella Gobbi; Luigi Janiri
Journal:  Psychopharmacology (Berl)       Date:  2006-02-22       Impact factor: 4.530

5.  Acute effects of sodium valproate and gamma-vinyl GABA on regional amino acid metabolism in the rat brain: incorporation of 2-[14C]glucose into amino acids.

Authors:  A G Chapman; K Riley; M C Evans; B S Meldrum
Journal:  Neurochem Res       Date:  1982-09       Impact factor: 3.996

6.  Valproate enhances GABA-A mediated inhibition of locus coeruleus neurones in vitro.

Authors:  H R Olpe; M W Steinmann; M F Pozza; F Brugger; M Schmutz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

7.  Testing of prototype antiepileptics in hippocampal slices.

Authors:  G M Rose; H R Olpe; H L Haas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

8.  Effects of valproate on hyponeophagia in rats: competitive antagonism with picrotoxin and non-competitive antagonism with RO 15-1788.

Authors:  R A Shephard; D Stevenson; S Jenkinson
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  The role of different types of adrenergic receptors in pentylenetetrazol-induced seizures and the effect of di-n-propylacetate in the rat.

Authors:  M Lazarova; C Bendotti; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Studies on the role of serotonin in different regions of the rat central nervous system on pentylenetetrazol-induced seizures and the effect of di-n-propylacetate.

Authors:  M Lazarova; C Bendotti; R Samanin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.